Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy

Joseph A. Khawly; Peter Saloupis; Diane L. Hatchell; Robert Machemer

doi:10.1007/BF00166311

Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy

Joseph A. Khawly, Peter Saloupis, Diane L. Hatchell, Robert Machemer

Research output: Contribution to journal › Article › peer-review

65 Scopus citations

Abstract

A condition similar to proliferative vitreoretinopathy (PVR) in man can be produced by injecting 25000 homologous dermal fibroblasts into rabbit eyes following gas compression of the vitreous. Daunorubicin (15 nmol) was effective in preventing retinal detachment in this model when injected simultaneously with the fibroblasts or in two doses (10 nmol followed by 5 nmol 4 h later) on the 3rd day after fibroblast injection. A single dose of 15 nmol on the 3rd day was not effective in preventing retinal detachment. These results suggest that daunorubicin may be clinically useful in preventing PVR when given by injection both at the time of vitrectomy as well as later, when protein exudation and pigment clumps in the vitreous cavity herald the onset of PVR.

Original language	English (US)
Pages (from-to)	464-467
Number of pages	4
Journal	Graefe's Archive for Clinical and Experimental Ophthalmology
Volume	229
Issue number	5
DOIs	https://doi.org/10.1007/BF00166311
State	Published - Sep 1991

ASJC Scopus subject areas

Ophthalmology
Sensory Systems
Cellular and Molecular Neuroscience

Access to Document

10.1007/BF00166311

Cite this

@article{728b1ff450bd4034870dbb6bd2a81dd9,

title = "Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy",

abstract = "A condition similar to proliferative vitreoretinopathy (PVR) in man can be produced by injecting 25000 homologous dermal fibroblasts into rabbit eyes following gas compression of the vitreous. Daunorubicin (15 nmol) was effective in preventing retinal detachment in this model when injected simultaneously with the fibroblasts or in two doses (10 nmol followed by 5 nmol 4 h later) on the 3rd day after fibroblast injection. A single dose of 15 nmol on the 3rd day was not effective in preventing retinal detachment. These results suggest that daunorubicin may be clinically useful in preventing PVR when given by injection both at the time of vitrectomy as well as later, when protein exudation and pigment clumps in the vitreous cavity herald the onset of PVR.",

author = "Khawly, {Joseph A.} and Peter Saloupis and Hatchell, {Diane L.} and Robert Machemer",

year = "1991",

month = sep,

doi = "10.1007/BF00166311",

language = "English (US)",

volume = "229",

pages = "464--467",

journal = "Graefe's Archive for Clinical and Experimental Ophthalmology",

issn = "0721-832X",

publisher = "Springer Verlag",

number = "5",

}

TY - JOUR

T1 - Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy

AU - Khawly, Joseph A.

AU - Saloupis, Peter

AU - Hatchell, Diane L.

AU - Machemer, Robert

PY - 1991/9

Y1 - 1991/9

N2 - A condition similar to proliferative vitreoretinopathy (PVR) in man can be produced by injecting 25000 homologous dermal fibroblasts into rabbit eyes following gas compression of the vitreous. Daunorubicin (15 nmol) was effective in preventing retinal detachment in this model when injected simultaneously with the fibroblasts or in two doses (10 nmol followed by 5 nmol 4 h later) on the 3rd day after fibroblast injection. A single dose of 15 nmol on the 3rd day was not effective in preventing retinal detachment. These results suggest that daunorubicin may be clinically useful in preventing PVR when given by injection both at the time of vitrectomy as well as later, when protein exudation and pigment clumps in the vitreous cavity herald the onset of PVR.

AB - A condition similar to proliferative vitreoretinopathy (PVR) in man can be produced by injecting 25000 homologous dermal fibroblasts into rabbit eyes following gas compression of the vitreous. Daunorubicin (15 nmol) was effective in preventing retinal detachment in this model when injected simultaneously with the fibroblasts or in two doses (10 nmol followed by 5 nmol 4 h later) on the 3rd day after fibroblast injection. A single dose of 15 nmol on the 3rd day was not effective in preventing retinal detachment. These results suggest that daunorubicin may be clinically useful in preventing PVR when given by injection both at the time of vitrectomy as well as later, when protein exudation and pigment clumps in the vitreous cavity herald the onset of PVR.

UR - http://www.scopus.com/inward/record.url?scp=0025887051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025887051&partnerID=8YFLogxK

U2 - 10.1007/BF00166311

DO - 10.1007/BF00166311

M3 - Article

C2 - 1937080

AN - SCOPUS:0025887051

VL - 229

SP - 464

EP - 467

JO - Graefe's Archive for Clinical and Experimental Ophthalmology

JF - Graefe's Archive for Clinical and Experimental Ophthalmology

SN - 0721-832X

IS - 5

ER -

Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this